Work

Supplementary Figure S12 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial

Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 12. Multivariable analysis for overall survival in the SQUINT (A) and combined SQUINT + Dana-Farber Cancer Institute (B) cohorts. Multivariable analysis for progression free survival in the SQUINT (C) and combined SQUINT + Dana-Farber Cancer Institute (D) cohorts.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4408537596
Cites:
Cited by:
Related to: 9